MERKEL CELL CARCINOMA

This study is testing a treatment made from donated immune cells grown in a lab. These cells are designed to find and kill BK and JC viruses, which can cause serious infections in people with weakened immune systems, such as those with cancer, HIV, or a transplant. The goal is to…

This trial is testing whether giving two immunotherapy drugs before surgery can help people with a rare and aggressive skin cancer called Merkel cell carcinoma. The goal is to shrink the tumor and lower the chance of the cancer coming back after surgery. About 20 participants wit…

This study is testing an experimental treatment called RP1 for people who have had an organ or bone marrow transplant and now have advanced skin cancer. RP1 is a modified cold sore virus that is injected directly into tumors to try to destroy them and boost the body's immune resp…

This study is testing the safety and effectiveness of a new investigational drug called GI-101 for people with advanced or metastatic solid tumors. The drug is designed to work in two ways to help the immune system fight cancer. Researchers will test it alone and in combination w…

This early-stage trial is testing a new drug called CRD3874-SI in people with advanced cancers that have spread or returned after previous treatments. Researchers will first find the highest safe dose, then test that dose in patients with specific cancers like sarcoma and Merkel …

This early-stage study aims to find a safe and effective dose of a new drug called AZD6750, which is designed to boost the immune system to fight cancer. It will test the drug alone and combined with other cancer treatments in about 60 adults with advanced or spreading solid tumo…

This study is testing whether it is safe to combine a new targeted drug called tarlatamab with standard radiation therapy. It is for adults with advanced cancers that have a specific protein called DLL3, including certain lung cancers, melanoma, and others. The main goal is to se…

This study is testing a new oral medication called NEO212 for adults with specific aggressive brain tumors (like glioblastoma) or brain metastases from other cancers. The main goals are to find a safe and effective dose, see how the body processes the drug, and check if it can he…

This is an early-stage study to find a safe dose of an experimental therapy called MQ710 for people with advanced solid tumors that have returned, spread, or stopped responding to standard treatments. The therapy is a modified virus designed to be injected directly into tumors. R…

This study is testing a personalized treatment for people with advanced forms of skin cancer (cutaneous squamous cell carcinoma or Merkel cell carcinoma) that have come back after standard immunotherapy. Doctors take a patient's own immune cells from a tumor, grow large numbers o…

This study is testing if giving an immunotherapy drug called pembrolizumab before surgery helps people with a rare and aggressive skin cancer called Merkel cell carcinoma. The goal is to see if this approach shrinks the tumor and, most importantly, reduces the risk of the cancer …

This study is testing a shorter, more convenient radiation schedule for people with Merkel cell carcinoma, a rare and aggressive skin cancer. The goal is to see if giving higher doses of radiation over fewer visits is as effective at controlling the cancer and preventing it from …

This study is testing whether cancer patients prefer to receive their standard drug treatments at home instead of in a clinic. Researchers want to see if home-based care reduces the burden of travel and improves treatment satisfaction and quality of life for patients. A specializ…

This study is testing whether a numbing cream called EMLA can reduce the brief pain patients feel from injections during a lymph node mapping procedure for skin cancer. About 100 adults with melanoma, Merkel cell, or squamous cell skin cancer will be randomly assigned to use eith…

This study is testing a new predictive tool to see if it can accurately forecast which patients with melanoma and other cancers will respond to immunotherapy treatments. It will enroll 1,000 patients who are eligible for standard immunotherapy. The goal is to see if this tool can…